Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Gill and Richards request a full and rigorous assessment of the
benefits and costs of introducing new genetic screening tests.1 They point out the need for collaboration between
geneticists, public health specialists, and primary care teams and
emphasise the importance of the general public.
A spot analysis of data available for East Sussex, Brighton and Hove
Health Authority for the current financial year (1997-8) from an
eligible general population of roughly 730 000 shows at least 28 referrals to date for genetic testing, of which 18 were funded, six
were cancelled by the originator, and the remainder are still in
progress. Readiness to undergo testing involves the capacity of the
funding commissioners to ensure that there is a confirmed benefit to
the patient so that they can fund such testing. This is in concert with
one of the principles identified by Wilson and Jungner for successful
screening: "there should be an